Cure Parkinson's
At a glance
- Preclinical projects: up to £300k
- Clinical infrastructure projects and sub-studies: £75,000 to £300,000
Key takeaways
- Cure Parkinson's suits a research project aimed at disease-modifying Parkinson's treatment, whether preclinical or clinical, that could realistically reach people with Parkinson's within five years.
- It does not fund research directed only at symptomatic relief, and under its quarterly programme it excludes trials involving only healthy volunteers.
- Grants in the annual report have typically run from £150,000 to £5,750,000, with a median of £250,000, and stated programme limits are up to £300,000 for preclinical projects and £75,000 to £300,000 for clinical infrastructure projects and sub-studies, so only a project of that scale and scientific standing is likely to fit.
- Start with a Stage 1 application by a published deadline, which the charity says takes about 24 weeks to decide, and contact the research team before submitting late-stage or novel clinical trial designs.
- Applications are sent for external peer review, and eligibility is stated as academic and commercial entities working alone or together, so an organisation without research capacity should check its fit before applying.
Overview
Cure Parkinson's is a charity registered with the Charity Commission for England and Wales (charity number 1111816).
Cure Parkinson's exists to fund research that could hasten a cure for Parkinson's, a debilitating neurological condition. It was founded when four people with Parkinson's came together to build it. The annual report records £1,695,263 paid out in grants, funding both preclinical and clinical research projects with the potential to cure Parkinson's.
What they fund
Priority Areas
Cure Parkinson’s funds preclinical and clinical research projects with the potential to slow, stop or reverse Parkinson’s progression, focusing on disease-modifying treatments. It funds internationally and accepts applications from academic and commercial entities, working alone or in collaboration. Preclinical proposals are prioritised when they have a realistic prospect of reaching clinical testing in people with Parkinson’s within five years; clinical projects must involve people living with Parkinson’s. The independent research committee assesses proposals against the charity’s research strategy and scientific criteria, with applications of sufficient merit sent for external peer review before funding recommendations go to the trustees. Its approach encourages collaboration between researchers, patients and funders to accelerate progress for people living with Parkinson’s.
Themes
- Disease-modifying Parkinson's research
Geographic Focus
Internationally.
What they don't fund
- Research directed only to symptomatic relief
- Quarterly Research Grant Funding Programme only: trials only involving healthy volunteers
How to apply
Applicants submit a Stage 1 application for committee review; proposals selected for further consideration are invited to proceed to a full Stage 2 application.
Deadlines: Stage 1 applications are submitted by published deadlines.
Who can apply:
- Quarterly Research Grant Funding Programme
- We fund internationally; industry and academia alone or in collaboration. We fund both preclinical and clinical research projects. Clinical projects must involve people with Parkinson’s; we do not fund trials only involving healthy volunteers.
- All applicants must also be able to sign up to and comply with our grant terms and conditions outlined in the grant contract.
What to send:
- Quarterly Research Grant Funding Programme
- Stage 1 application form
- Any project involving a commercial entity must submit a commercial entity form as part of their grant submission.
- Budget template, only required at Stage 2 submission.
- For applicants working in a currency other than GBP, projects are required to submit budget costs and if successful, contract in GBP.
Application success factors
What the charity says:
- It prioritises research with a realistic prospect of translation to clinical testing within five years.
- Preclinical proposals must have a clinical candidate and an achievable timeline to clinical testing in people with Parkinson’s.
- Applications are evaluated against the research strategy and criteria including scientific rationale, originality, experimental protocol, budget and proximity to clinical transition.
- Applicants considering late-stage clinical trials or novel clinical trial designs are asked to contact the research team before submitting.
- Commercial application costs should be justified and equivalent to academic costs where possible.
Where they fund
Where it says it funds
Similar funders
Funders that often appear alongside Cure Parkinson's in recipients' filed accounts.
Grants
How much do they typically give?
Share of 9 grants in year to 31 March 2025 by size
Median £250k (year to 31 March 2025)
The largest grants to organisations in this funder’s latest annual report:
- NIHR · Ejs act-pd£5,713,171year to 31 March 2025
- University of Cambridge · Dapa-pd£1,065,402year to 31 March 2025
- University College London · Target Trial Emulation; Exenatide; KTP; PD Frontline£463,673year to 31 March 2025
- University of Sheffield · Repurposing Anti-Gout Medications; PD-CSG; iLCT Screen£278,499year to 31 March 2025
- University of Helsinki (Finland) · CDNF and MANF mimetics£250,000year to 31 March 2025
- University of Pittsburgh (USA) · CP-6 nitroalkene in PD£196,946year to 31 March 2025
- University of Buffalo (USA) · Low Dose Lithium£193,635year to 31 March 2025
- University of Coimbra (Portugal) · GAin-PD£173,509year to 31 March 2025
All 9 grants in the year to 31 March 2025
- NIHR · Ejs act-pd£5,713,171
- University of Cambridge · Dapa-pd£1,065,402
- University College London · Target Trial Emulation; Exenatide; KTP; PD Frontline£463,673
- University of Sheffield · Repurposing Anti-Gout Medications; PD-CSG; iLCT Screen£278,499
- University of Helsinki (Finland) · CDNF and MANF mimetics£250,000
- University of Pittsburgh (USA) · CP-6 nitroalkene in PD£196,946
- University of Buffalo (USA) · Low Dose Lithium£193,635
- University of Coimbra (Portugal) · GAin-PD£173,509
- German Center for Neurodegenerative Diseases (Germany) · Evaluation Of Carnosic Acid£152,193
Grant examples taken from the funder’s filed accounts. Not included above: 1 with no amount stated.
Five years of accounts
- Income
- £2,451,267
- Expenditure
- £2,015,856
- Grants paid
- £498,507
- Income
- £2,446,239
- Expenditure
- £2,764,689
- Grants paid
- £1,381,007
- Income
- £4,592,264
- Expenditure
- £3,526,300
- Grants paid
- £851,914
- Income
- £9,379,079
- Expenditure
- £7,771,048
- Grants paid
- £5,418,839
- Income
- £14,981,860
- Expenditure
- £11,239,428
- Grants paid
- £1,695,263
| Financial year | Income | Expenditure | Grants paid | Accounts document |
|---|---|---|---|---|
| year to 31 December 2020 | £2,451,267 | £2,015,856 | £498,507 | Accounts for year to 31 December 2020 |
| year to 31 December 2021 | £2,446,239 | £2,764,689 | £1,381,007 | Accounts for year to 31 December 2021 |
| year to 31 March 2023 | £4,592,264 | £3,526,300 | £851,914 | Accounts for year to 31 March 2023 |
| year to 31 March 2024 | £9,379,079 | £7,771,048 | £5,418,839 | Accounts for year to 31 March 2024 |
| year to 31 March 2025 | £14,981,860 | £11,239,428 | £1,695,263 | Accounts for year to 31 March 2025 |
Income vs grants paid
IncomeGrants paid
Total value each financial year
Grants paid stayed within income across the 5 years shown.
- Grants paid, year to 31 December 2020; year to 31 December 2021; year to 31 March 2023; year to 31 March 2024: grants to institutions, as reported on the charity register (Part B).
- Grants paid, year to 31 March 2025: grants paid out in the year.
Figures from the charity’s filed accounts and its register entry. The document icon links to the charity’s entry on the Charity Commission register, where its filed accounts can be found.
Sources
Registers and filings
Other sources
- cureparkinsons.org.uk
- cureparkinsons.org.uk/research/for-researchers/apply-for-funding · read on 31 October 2026
- cureparkinsons.org.uk/research/for-researchers/apply-for-funding/quarterly-research-grant · read on 31 October 2026
- cureparkinsons.org.uk/research/our-approach · read on 31 October 2026
- cureparkinsons.org.uk/about-us · read on 31 October 2026
- cureparkinsons.org.uk/get-involved/donate · read on 31 October 2026
- Annual report (year to 31 March 2025)
This profile draws on the funder’s own website as well as its filed accounts.
Sources last checked on 31 October 2026.
🎯 You've done the research. Now write an application they can't refuse.
Hinchilla combines funder's specific priorities with your organisation's past successful grants and AI analysis of what reviewers want to see.
Data privacy and security by default
Your organisation's past successful grants and experience
AI analysis of what reviewers want to see
A compelling draft application in 10 minutes instead of 10 hours
Spotted something that needs correcting? Let us know
At a glance
- Preclinical projects: up to £300k
- Clinical infrastructure projects and sub-studies: £75,000 to £300,000

Applying to Cure Parkinson's?
Hinchilla drafts your answers around this funder's priorities, using your organisation's own documents.
No credit card required
Contact
- 0207 487 3892source
- research@cureparkinsons.org.uksource
- Rosa@cureparkinsons.org.uksource
- info@cureparkinsons.org.uksource
- Cure Parkinson’s, 120 New Cavendish Street, London W1W 6XXsource
- cureparkinsons.org.uk

Applying to Cure Parkinson's?
Hinchilla drafts your answers around this funder's priorities, using your organisation's own documents.
No credit card required
Contact
- 0207 487 3892source
- research@cureparkinsons.org.uksource
- Rosa@cureparkinsons.org.uksource
- info@cureparkinsons.org.uksource
- Cure Parkinson’s, 120 New Cavendish Street, London W1W 6XXsource
- cureparkinsons.org.uk